The Therapeutic Potential of Chemokines in the Treatment of Chemotherapy- Induced Peripheral Neuropathy

doi:10.2174/1389450120666190906153652
摘要

背景: 目前癌症治疗的一些挑战和并发症是化疗引起的周围神经病变(CIPN)和与这种情况相关的神经痛。许多主要的化疗药物可引起神经毒性，对免疫系统有显著的调节作用，并常伴有各种不良反应。最近的证据表明，在化疗期间，神经系统和免疫系统之间会发生串音;因此，一个新出现的概念是，神经炎症是CIPN的主要机制之一，这已被趋化因子的上调所证实。趋化因子最初被认为是外周免疫细胞转运的调节因子，在中枢神经系统的神经元和胶质细胞上也有表达。目的: 在这篇综述中，我们收集的证据表明趋化因子是CIPN疼痛信号的潜在介质和贡献者。趋化因子及其受体CX3CL1/CX3CR1、CCL2/CCR2、CXCL1/CXCR2、CXCL12/CXCR4、CCL3/CCR5在CIPN病理状态下表达改变，趋化因子受体拮抗剂可减轻神经性疼痛行为。结论:通过对趋化因子介导的通讯机制的了解，我们可能发现趋化因子靶点可以作为治疗CIPN的新策略。
关键词: 化疗所致周围神经病变，化疗药物，趋化因子，神经炎症，CCL2
« Previous Next »
图形摘要

[1] 
Marmiroli P, Scuteri A, Cornblath DR, Cavaletti G. Pain in chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst  2017; 22(3): 156-61.
[http://dx.doi.org/10.1111/jns.12226] [PMID:  28600844] 
[2] 
Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol Oncol  2016; 140(1): 176-83.
[http://dx.doi.org/10.1016/j.ygyno.2015.11.011] [PMID:  26556766] 
[3] 
Fallon MT. Neuropathic pain in cancer. Br J Anaesth  2013; 111(1): 105-11.
[http://dx.doi.org/10.1093/bja/aet208] [PMID:  23794652] 
[4] 
Ma J, Kavelaars A, Dougherty PM, Heijnen CJ. Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source. Cancer  2018; 124(11): 2289-98.
[http://dx.doi.org/10.1002/cncr.31248] [PMID:  29461625] 
[5] 
Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain  2014; 155(12): 2461-70.
[http://dx.doi.org/10.1016/j.pain.2014.09.020] [PMID:  25261162] 
[6] 
Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev  2014; 40(7): 872-82.
[http://dx.doi.org/10.1016/j.ctrv.2014.04.004] [PMID:  24830939] 
[7] 
Hama A, Takamatsu H. Chemotherapy-Induced Peripheral Neuropathic Pain and Rodent Models. CNS Neurol Disord Drug Targets  2016; 15(1): 7-19.
[http://dx.doi.org/10.2174/1871527315666151110125325] [PMID:  26553161] 
[8] 
Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies-a growing problem for patients and health care providers. Brain Behav  2016; 7(1)e00558
[http://dx.doi.org/10.1002/brb3.558] [PMID:  28127506] 
[9] 
Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci  2017; 10: 174.
[http://dx.doi.org/10.3389/fnmol.2017.00174] [PMID:  28620280] 
[10] 
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci  2019; 20(6)E1451
[http://dx.doi.org/10.3390/ijms20061451] [PMID:  30909387] 
[11] 
Waseem M, Kaushik P, Tabassum H, Parvez S. Role of mitochondrial mechanism in chemotherapy-induced peripheral neuropathy. Curr Drug Metab  2018; 19(1): 47-54.
[http://dx.doi.org/10.2174/1389200219666171207121313] [PMID:  29219049] 
[12] 
Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol  2013; 4: 156.
[http://dx.doi.org/10.3389/fphar.2013.00156] [PMID:  24385965] 
[13] 
Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology  2012; 291(1-3): 1-9.
[http://dx.doi.org/10.1016/j.tox.2011.10.019] [PMID:  22079234] 
[14] 
Authier N, Balayssac D, Marchand F, et al. Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics  2009; 6(4): 620-9.
[http://dx.doi.org/10.1016/j.nurt.2009.07.003] [PMID:  19789067] 
[15] 
Boyle FM, Beatson C, Monk R, Grant SL, Kurek JB. The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother Pharmacol  2001; 48(6): 429-34.
[http://dx.doi.org/10.1007/s00280-001-0382-6] [PMID:  11800022] 
[16] 
Boyle FM, Wheeler HR, Shenfield GM. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol  1999; 41(2): 107-16.
[http://dx.doi.org/10.1023/A:1006124917643] [PMID:  10222430] 
[17] 
Flatters SJL, Dougherty PM, Colvin LA. clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review. Br J Anaesth  2017; 119(4): 737-49.
[http://dx.doi.org/10.1093/bja/aex229] [PMID:  29121279] 
[18] 
Cioroiu C, Weimer LH. Update on Chemotherapy-Induced Peripheral Neuropathy. Curr Neurol Neurosci Rep  2017; 17(6): 47.
[http://dx.doi.org/10.1007/s11910-017-0757-7] [PMID:  28421360] 
[19] 
Di Cesare Mannelli L, Zanardelli M, Landini I, et al. Effect of the SOD mimetic MnL4 on in vitro and in vivo oxaliplatin toxicity: Possible aid in chemotherapy induced neuropathy. Free Radic Biol Med  2016; 93: 67-76.
[http://dx.doi.org/10.1016/j.freeradbiomed.2016.01.023] [PMID:  26828020] 
[20] 
Storey DJ, Sakala M, McLean CM, et al. Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy? Ann Oncol  2010; 21(8): 1657-61.
[http://dx.doi.org/10.1093/annonc/mdp594] [PMID:  20089559] 
[21] 
Carvalho LF, Silva AMF, Carvalho AA. The use of antioxidant agents for chemotherapy-induced peripheral neuropathy treatment in animal models. Clin Exp Pharmacol Physiol  2017; 44(10): 971-9.
[http://dx.doi.org/10.1111/1440-1681.12803] [PMID:  28649767] 
[22] 
Babu A, Prasanth KG, Balaji B. Effect of curcumin in mice model of vincristine-induced neuropathy. Pharm Biol  2015; 53(6): 838-48.
[http://dx.doi.org/10.3109/13880209.2014.943247] [PMID:  25429779] 
[23] 
Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol  2000; 424(4): 563-76.
[http://dx.doi.org/10.1002/1096-9861(20000904)424:4<563::AID-CNE1>3.0.CO;2-U] [PMID: 10931481] 
[24] 
Lopus M, Smiyun G, Miller H, Oroudjev E, Wilson L, Jordan MA. Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype. Cancer Chemother Pharmacol  2015; 76(5): 1013-24.
[http://dx.doi.org/10.1007/s00280-015-2863-z] [PMID:  26416565] 
[25] 
Vahdat LT, Thomas ES, Roché HH, et al. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer  2012; 20(11): 2661-8.
[http://dx.doi.org/10.1007/s00520-012-1384-0] [PMID:  22382588] 
[26] 
Thawani SP, Tanji K, De Sousa EA, Weimer LH, Brannagan TH III. Bortezomib-associated demyelinating neuropathy--clinical and pathologic features. J Clin Neuromuscul Dis  2015; 16(4): 202-9.
[http://dx.doi.org/10.1097/CND.0000000000000077] [PMID:  25996966] 
[27] 
Farquhar-Smith P. Chemotherapy-induced neuropathic pain. Curr Opin Support Palliat Care  2011; 5(1): 1-7.
[http://dx.doi.org/10.1097/SPC.0b013e328342f9cc] [PMID:  21192267] 
[28] 
Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. Drug Des Devel Ther  2012; 6: 371-84.
[PMID:  23251087] 
[29] 
De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S. Taxane induced neuropathy in patients affected by breast cancer: Literature review. Crit Rev Oncol Hematol  2015; 96(1): 34-45.
[http://dx.doi.org/10.1016/j.critrevonc.2015.04.011] [PMID:  26004917] 
[30] 
Richardson P, Hideshima T, Anderson K. Thalidomide in multiple myeloma. Biomed Pharmacother  2002; 56(3): 115-28.
[http://dx.doi.org/10.1016/S0753-3322(02)00168-3] [PMID:  12046682] 
[31] 
Morawska M, Grzasko N, Kostyra M, Wojciechowicz J, Hus M. Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol  2015; 33(4): 113-9.
[http://dx.doi.org/10.1002/hon.2149] [PMID:  25399783] 
[32] 
Gao YJ, Zhang L, Samad OA, et al. JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci  2009; 29(13): 4096-108.
[http://dx.doi.org/10.1523/JNEUROSCI.3623-08.2009] [PMID:  19339605] 
[33] 
White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA  2007; 104(51): 20151-8.
[http://dx.doi.org/10.1073/pnas.0709250104] [PMID:  18083844] 
[34] 
Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol  2004; 25(2): 75-84.
[http://dx.doi.org/10.1016/j.it.2003.12.005] [PMID:  15102366] 
[35] 
Bajetto A, Bonavia R, Barbero S, Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem  2002; 82(6): 1311-29.
[http://dx.doi.org/10.1046/j.1471-4159.2002.01091.x] [PMID:  12354279] 
[36] 
Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity  2000; 12(2): 121-7.
[http://dx.doi.org/10.1016/S1074-7613(00)80165-X] [PMID:  10714678] 
[37] 
Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther  2010; 126(1): 56-68.
[http://dx.doi.org/10.1016/j.pharmthera.2010.01.002] [PMID:  20117131] 
[38] 
Zhang ZJ, Jiang BC, Gao YJ. Chemokines in neuron-glial cell interaction and pathogenesis of neuropathic pain. Cell Mol Life Sci  2017; 74(18): 3275-91.
[http://dx.doi.org/10.1007/s00018-017-2513-1] [PMID:  28389721] 
[39] 
Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev  2000; 52(1): 145-76.
[PMID:  10699158] 
[40] 
Schall TJ, Proudfoot AE. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol  2011; 11(5): 355-63.
[http://dx.doi.org/10.1038/nri2972] [PMID:  21494268] 
[41] 
Old EA, Malcangio M. Chemokine mediated neuron-glia communication and aberrant signalling in neuropathic pain states. Curr Opin Pharmacol  2012; 12(1): 67-73.
[http://dx.doi.org/10.1016/j.coph.2011.10.015] [PMID:  22056024] 
[42] 
Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol  2000; 18: 217-42.
[http://dx.doi.org/10.1146/annurev.immunol.18.1.217] [PMID:  10837058] 
[43] 
Limatola C, Giovannelli A, Maggi L, et al. SDF-1alpha-mediated modulation of synaptic transmission in rat cerebellum. Eur J Neurosci  2000; 12(7): 2497-504.
[http://dx.doi.org/10.1046/j.1460-9568.2000.00139.x] [PMID:  10947825] 
[44] 
Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A. Chemokines and chemokine receptors: an overview. Front Biosci  2009; 14: 540-51.
[http://dx.doi.org/10.2741/3261] [PMID:  19273084] 
[45] 
Oh SB, Tran PB, Gillard SE, Hurley RW, Hammond DL, Miller RJ. Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci  2001; 21(14): 5027-35.
[http://dx.doi.org/10.1523/JNEUROSCI.21-14-05027.2001] [PMID:  11438578] 
[46] 
Abbadie C, Lindia JA, Cumiskey AM, et al. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci USA  2003; 100(13): 7947-52.
[http://dx.doi.org/10.1073/pnas.1331358100] [PMID:  12808141] 
[47] 
Abbadie C. Chemokines, chemokine receptors and pain. Trends Immunol  2005; 26(10): 529-34.
[http://dx.doi.org/10.1016/j.it.2005.08.001] [PMID:  16099720] 
[48] 
Kiguchi N, Kobayashi Y, Maeda T, Saika F, Kishioka S. CC-chemokine MIP-1α in the spinal cord contributes to nerve injury-induced neuropathic pain. Neurosci Lett  2010; 484(1): 17-21.
[http://dx.doi.org/10.1016/j.neulet.2010.07.085] [PMID:  20692319] 
[49] 
White FA, Bhangoo SK, Miller RJ. Chemokines: integrators of pain and inflammation. Nat Rev Drug Discov  2005; 4(10): 834-44.
[http://dx.doi.org/10.1038/nrd1852] [PMID:  16224455] 
[50] 
Manjavachi MN, Quintão NL, Campos MM, et al. The effects of the selective and non-peptide CXCR2 receptor antagonist SB225002 on acute and long-lasting models of nociception in mice. Eur J Pain  2010; 14(1): 23-31.
[http://dx.doi.org/10.1016/j.ejpain.2009.01.007] [PMID:  19264522] 
[51] 
Rittner HL, Labuz D, Schaefer M, et al. Pain control by CXCR2 ligands through Ca2+-regulated release of opioid peptides from polymorphonuclear cells. FASEB J  2006; 20(14): 2627-9.
[http://dx.doi.org/10.1096/fj.06-6077fje] [PMID:  17060402] 
[52] 
Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain  1988; 33(1): 87-107.
[http://dx.doi.org/10.1016/0304-3959(88)90209-6] [PMID:  2837713] 
[53] 
Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain  2000; 87(2): 149-58.
[http://dx.doi.org/10.1016/S0304-3959(00)00276-1] [PMID:  10924808] 
[54] 
Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain  1992; 50(3): 355-63.
[http://dx.doi.org/10.1016/0304-3959(92)90041-9] [PMID:  1333581] 
[55] 
Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain  1990; 43(2): 205-18.
[http://dx.doi.org/10.1016/0304-3959(90)91074-S] [PMID:  1982347] 
[56] 
Hu SJ, Xing JL. An experimental model for chronic compression of dorsal root ganglion produced by intervertebral foramen stenosis in the rat. Pain  1998; 77(1): 15-23.
[http://dx.doi.org/10.1016/S0304-3959(98)00067-0] [PMID:  9755014] 
[57] 
Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev  1999; 10(1): 61-86.
[http://dx.doi.org/10.1016/S1359-6101(99)00005-2] [PMID:  10379912] 
[58] 
Kurihara T, Bravo R. Cloning and functional expression of mCCR2, a murine receptor for the C-C chemokines JE and FIC. J Biol Chem  1996; 271(20): 11603-7.
[http://dx.doi.org/10.1074/jbc.271.20.11603] [PMID:  8662823] 
[59] 
Abbadie C, Bhangoo S, De Koninck Y, Malcangio M, Melik-Parsadaniantz S, White FA. Chemokines and pain mechanisms. Brain Res Brain Res Rev  2009; 60(1): 125-34.
[http://dx.doi.org/10.1016/j.brainresrev.2008.12.002] [PMID:  19146875] 
[60] 
Bhangoo SK, Ripsch MS, Buchanan DJ, Miller RJ, White FA. Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy. Mol Pain  2009; 5: 48.
[http://dx.doi.org/10.1186/1744-8069-5-48] [PMID:  19674450] 
[61] 
Guo W, Wang H, Zou S, Dubner R, Ren K. Chemokine signaling involving chemokine (C-C motif) ligand 2 plays a role in descending pain facilitation. Neurosci Bull  2012; 28(2): 193-207.
[http://dx.doi.org/10.1007/s12264-012-1218-6] [PMID:  22466130] 
[62] 
Van Steenwinckel J, Reaux-Le Goazigo A, Pommier B, et al. CCL2 released from neuronal synaptic vesicles in the spinal cord is a major mediator of local inflammation and pain after peripheral nerve injury. J Neurosci  2011; 31(15): 5865-75.
[http://dx.doi.org/10.1523/JNEUROSCI.5986-10.2011] [PMID:  21490228] 
[63] 
Zhang ZJ, Dong YL, Lu Y, Cao S, Zhao ZQ, Gao YJ. Chemokine CCL2 and its receptor CCR2 in the medullary dorsal horn are involved in trigeminal neuropathic pain. J Neuroinflammation  2012; 9: 136.
[http://dx.doi.org/10.1186/1742-2094-9-136] [PMID:  22721162] 
[64] 
Gornstein E, Schwarz TL. The paradox of paclitaxel neurotoxicity:
 Mechanisms and unanswered questions. Neuropharmacology  2014; 76(Pt A): 175-83.
[65] 
Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin  2013; 63(6): 419-37.
[http://dx.doi.org/10.3322/caac.21204] [PMID:  24590861] 
[66] 
McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther  2009; 8(1): 10-6.
[http://dx.doi.org/10.1158/1535-7163.MCT-08-0840] [PMID:  19139108] 
[67] 
Warwick RA, Hanani M. The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. Eur J Pain  2013; 17(4): 571-80.
[http://dx.doi.org/10.1002/j.1532-2149.2012.00219.x] [PMID:  23065831] 
[68] 
Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci  2009; 10(1): 23-36.
[http://dx.doi.org/10.1038/nrn2533] [PMID:  19096368] 
[69] 
Zhang H, Boyette-Davis JA, Kosturakis AK, et al. Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy. J Pain  2013; 14(10): 1031-44.
[http://dx.doi.org/10.1016/j.jpain.2013.03.012] [PMID:  23726937] 
[70] 
Sun JH, Yang B, Donnelly DF, Ma C, LaMotte RH. MCP-1 enhances excitability of nociceptive neurons in chronically compressed dorsal root ganglia. J Neurophysiol  2006; 96(5): 2189-99.
[http://dx.doi.org/10.1152/jn.00222.2006] [PMID:  16775210] 
[71] 
White FA, Sun J, Waters SM, et al. Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc Natl Acad Sci USA  2005; 102(39): 14092-7.
[http://dx.doi.org/10.1073/pnas.0503496102] [PMID:  16174730] 
[72] 
Jung H, Bhangoo S, Banisadr G, et al. Visualization of chemokine receptor activation in transgenic mice reveals peripheral activation of CCR2 receptors in states of neuropathic pain. J Neurosci  2009; 29(25): 8051-62.
[http://dx.doi.org/10.1523/JNEUROSCI.0485-09.2009] [PMID:  19553445] 
[73] 
Devor M, Wall PD. Cross-excitation in dorsal root ganglia of nerve-injured and intact rats. J Neurophysiol  1990; 64(6): 1733-46.
[http://dx.doi.org/10.1152/jn.1990.64.6.1733] [PMID:  2074461] 
[74] 
Oh EJ, Weinreich D. Chemical communication between vagal afferent somata in nodose Ganglia of the rat and the Guinea pig in vitro. J Neurophysiol  2002; 87(6): 2801-7.
[http://dx.doi.org/10.1152/jn.2002.87.6.2801] [PMID:  12037182] 
[75] 
Boyette-Davis JA, Cata JP, Zhang H, et al. Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. J Pain  2011; 12(9): 1017-24.
[http://dx.doi.org/10.1016/j.jpain.2011.04.008] [PMID:  21703938] 
[76] 
Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol  2009; 27(21): 3518-25.
[http://dx.doi.org/10.1200/JCO.2008.18.3087] [PMID:  19528374] 
[77] 
Cook DN. The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukoc Biol  1996; 59(1): 61-6.
[http://dx.doi.org/10.1002/jlb.59.1.61] [PMID:  8558069] 
[78] 
Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev  2002; 13(6): 455-81.
[http://dx.doi.org/10.1016/S1359-6101(02)00045-X] [PMID:  12401480] 
[79] 
Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res  2009; 29(6): 313-26.
[http://dx.doi.org/10.1089/jir.2008.0027] [PMID:  19441883] 
[80] 
Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol  2010; 229(1-2): 26-50.
[http://dx.doi.org/10.1016/j.jneuroim.2010.08.013] [PMID:  20870295] 
[81] 
Elson K, Speck P, Simmons A. Herpes simplex virus infection of murine sensory ganglia induces proliferation of neuronal satellite cells. J Gen Virol  2003; 84(Pt 5): 1079-84.
[http://dx.doi.org/10.1099/vir.0.19035-0] [PMID:  12692271] 
[82] 
Takeda M, Tanimoto T, Kadoi J, et al. Enhanced excitability of nociceptive trigeminal ganglion neurons by satellite glial cytokine following peripheral inflammation. Pain  2007; 129(1-2): 155-66.
[http://dx.doi.org/10.1016/j.pain.2006.10.007] [PMID:  17127002] 
[83] 
Li Y, Zhang H, Kosturakis AK, et al. MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy. Brain Behav Immun  2015; 49: 255-66.
[http://dx.doi.org/10.1016/j.bbi.2015.06.003] [PMID:  26065826] 
[84] 
Li Y, Zhang H, Zhang H, Kosturakis AK, Jawad AB, Dougherty PM. Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy. J Pain  2014; 15(7): 712-25.
[http://dx.doi.org/10.1016/j.jpain.2014.04.001] [PMID:  24755282] 
[85] 
Makker PG, Duffy SS, Lees JG, et al. Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy. PLoS One  2017; 12(1)e0170814
[http://dx.doi.org/10.1371/journal.pone.0170814] [PMID:  28125674] 
[86] 
Al-Mazidi S, Alotaibi M, Nedjadi T, Chaudhary A, Alzoghaibi M, Djouhri L. Blocking of cytokines signalling attenuates evoked and spontaneous neuropathic pain behaviours in the paclitaxel rat model of chemotherapy-induced neuropathy. Eur J Pain  2018; 22(4): 810-21.
[http://dx.doi.org/10.1002/ejp.1169] [PMID:  29282807] 
[87] 
Zhang H, Li Y, de Carvalho-Barbosa M, et al. Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy. J Pain  2016; 17(7): 775-86.
[http://dx.doi.org/10.1016/j.jpain.2016.02.011] [PMID:  26979998] 
[88] 
Curry ZA, Wilkerson JL, Bagdas D, et al. Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and Proinflammatory markers in a mouse model of chemotherapy-induced neuropathy. J Pharmacol Exp Ther  2018; 366(1): 169-83.
[http://dx.doi.org/10.1124/jpet.117.245704] [PMID:  29540562] 
[89] 
Illias AM, Gist AC, Zhang H, Kosturakis AK, Dougherty PM. Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatin-induced mechanical hypersensitivity. Pain  2018; 159(7): 1308-16.
[http://dx.doi.org/10.1097/j.pain.0000000000001212] [PMID:  29554018] 
[90] 
Ju G, Hökfelt T, Brodin E, et al. Primary sensory neurons of the rat showing calcitonin gene-related peptide immunoreactivity and their relation to substance P-, somatostatin-, galanin-, vasoactive intestinal polypeptide- and cholecystokinin-immunoreactive ganglion cells. Cell Tissue Res  1987; 247(2): 417-31.
[http://dx.doi.org/10.1007/BF00218323] [PMID:  2434236] 
[91] 
Li L, Rutlin M, Abraira VE, et al. The functional organization of cutaneous low-threshold mechanosensory neurons. Cell  2011; 147(7): 1615-27.
[http://dx.doi.org/10.1016/j.cell.2011.11.027] [PMID:  22196735] 
[92] 
Wang H, Rivero-Melián C, Robertson B, Grant G. Transganglionic transport and binding of the isolectin B4 from Griffonia simplicifolia I in rat primary sensory neurons. Neuroscience  1994; 62(2): 539-51.
[http://dx.doi.org/10.1016/0306-4522(94)90387-5] [PMID:  7530347] 
[93] 
Montague K, Simeoli R, Valente J, Malcangio M. A novel interaction between CX3CR1 and CCR2 signalling in monocytes constitutes an underlying mechanism for persistent vincristine-induced pain. J Neuroinflammation  2018; 15(1): 101.
[http://dx.doi.org/10.1186/s12974-018-1116-6] [PMID:  29625610] 
[94] 
Curran MP, McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs  2009; 69(7): 859-88.
[http://dx.doi.org/10.2165/00003495-200969070-00006] [PMID:  19441872] 
[95] 
Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood  2008; 111(5): 2516-20.
[http://dx.doi.org/10.1182/blood-2007-10-116129] [PMID:  17975015] 
[96] 
Liu C, Luan S, OuYang H, et al. Upregulation of CCL2 via ATF3/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy. Brain Behav Immun  2016; 53: 96-104.
[http://dx.doi.org/10.1016/j.bbi.2015.11.004] [PMID:  26554515] 
[97] 
Zhang H, Yoon SY, Zhang H, Dougherty PM. Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. J Pain  2012; 13(3): 293-303.
[http://dx.doi.org/10.1016/j.jpain.2011.12.002] [PMID:  22285612] 
[98] 
Wang YS, Li YY, Cui W, et al. Melatonin Attenuates Pain Hypersensitivity and Decreases Astrocyte-Mediated Spinal Neuroinflammation in a Rat Model of Oxaliplatin-Induced Pain. Inflammation  2017; 40(6): 2052-61.
[http://dx.doi.org/10.1007/s10753-017-0645-y] [PMID:  28812173] 
[99] 
Pan Y, Lloyd C, Zhou H, et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature  1997; 387(6633): 611-7.
[http://dx.doi.org/10.1038/42491] [PMID:  9177350] 
[100] 
Verge GM, Milligan ED, Maier SF, Watkins LR, Naeve GS, Foster AC. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci  2004; 20(5): 1150-60.
[http://dx.doi.org/10.1111/j.1460-9568.2004.03593.x] [PMID:  15341587] 
[101] 
Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, Strijbos PJ. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci  2000; 20(15): RC87.
[http://dx.doi.org/10.1523/JNEUROSCI.20-15-j0004.2000] [PMID:  10899174] 
[102] 
Kim KW, Vallon-Eberhard A, Zigmond E, et al. In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood  2011; 118(22): e156-67.
[http://dx.doi.org/10.1182/blood-2011-04-348946] [PMID:  21951685] 
[103] 
Lindia JA, McGowan E, Jochnowitz N, Abbadie C. Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J Pain  2005; 6(7): 434-8.
[http://dx.doi.org/10.1016/j.jpain.2005.02.001] [PMID:  15993821] 
[104] 
Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature  1997; 385(6617): 640-4.
[http://dx.doi.org/10.1038/385640a0] [PMID:  9024663] 
[105] 
Clark AK, Malcangio M. Microglial signalling mechanisms: Cathepsin S and Fractalkine. Exp Neurol  2012; 234(2): 283-92.
[http://dx.doi.org/10.1016/j.expneurol.2011.09.012] [PMID:  21946268] 
[106] 
Clark AK, Staniland AA, Malcangio M. Fractalkine/CX3CR1 signalling in chronic pain and inflammation. Curr Pharm Biotechnol  2011; 12(10): 1707-14.
[http://dx.doi.org/10.2174/138920111798357465] [PMID:  21466443] 
[107] 
Huang ZZ, Li D, Ou-Yang HD, et al. Cerebrospinal fluid oxaliplatin contributes to the acute pain induced by systemic administration of oxaliplatin. Anesthesiology  2016; 124(5): 1109-21.
[http://dx.doi.org/10.1097/ALN.0000000000001084] [PMID:  26978408] 
[108] 
Li D, Huang ZZ, Ling YZ, et al. Up-regulation of cx3cl1 via nuclear factor-κb-dependent histone acetylation is involved in paclitaxel-induced peripheral neuropathy. Anesthesiology  2015; 122(5): 1142-51.
[http://dx.doi.org/10.1097/ALN.0000000000000560] [PMID:  25494456] 
[109] 
Huang ZZ, Li D, Liu CC, et al. CX3CL1-mediated macrophage activation contributed to paclitaxel-induced DRG neuronal apoptosis and painful peripheral neuropathy. Brain Behav Immun  2014; 40: 155-65.
[http://dx.doi.org/10.1016/j.bbi.2014.03.014] [PMID:  24681252] 
[110] 
Montague K, Malcangio M. The therapeutic potential of monocyte/macrophage manipulation in the treatment of chemotherapy-induced painful neuropathy. Front Mol Neurosci  2017; 10: 397.
[http://dx.doi.org/10.3389/fnmol.2017.00397] [PMID:  29230166] 
[111] 
Carlin LM, Stamatiades EG, Auffray C, et al. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell  2013; 153(2): 362-75.
[http://dx.doi.org/10.1016/j.cell.2013.03.010] [PMID:  23582326] 
[112] 
Schwarz N, Pruessmeyer J, Hess FM, et al. Requirements for leukocyte transmigration via the transmembrane chemokine CX3CL1. Cell Mol Life Sci  2010; 67(24): 4233-48.
[http://dx.doi.org/10.1007/s00018-010-0433-4] [PMID:  20559678] 
[113] 
Old EA, Nadkarni S, Grist J, et al. Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain. J Clin Invest  2014; 124(5): 2023-36.
[http://dx.doi.org/10.1172/JCI71389] [PMID:  24743146] 
[114] 
Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, Ji RR. Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav Immun  2007; 21(5): 642-51.
[http://dx.doi.org/10.1016/j.bbi.2006.11.003] [PMID:  17174525] 
[115] 
Fonović UP, Jevnikar Z, Kos J. Cathepsin S generates soluble CX3CL1 (fractalkine) in vascular smooth muscle cells. Biol Chem  2013; 394(10): 1349-52.
[http://dx.doi.org/10.1515/hsz-2013-0189] [PMID:  23893684] 
[116] 
Clark AK, Yip PK, Grist J, et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci USA  2007; 104(25): 10655-60.
[http://dx.doi.org/10.1073/pnas.0610811104] [PMID:  17551020] 
[117] 
Wang J, Zhang XS, Tao R, et al. Upregulation of CX3CL1 mediated by NF-κB activation in dorsal root ganglion contributes to peripheral sensitization and chronic pain induced by oxaliplatin administration. Mol Pain 2017.131744806917726256
[http://dx.doi.org/10.1177/1744806917726256] [PMID:  28849713] 
[118] 
Salem ML, Al-Khami AA, El-Naggar SA, Díaz-Montero CM, Chen Y, Cole DJ. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J Immunol  2010; 184(4): 1737-47.
[http://dx.doi.org/10.4049/jimmunol.0902309] [PMID:  20083664] 
[119] 
Nakahara T, Uchi H, Lesokhin AM, et al. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood  2010; 115(22): 4384-92.
[http://dx.doi.org/10.1182/blood-2009-11-251231] [PMID:  20154220] 
[120] 
Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol  2011; 186(2): 807-15.
[http://dx.doi.org/10.4049/jimmunol.1001483] [PMID:  21148040] 
[121] 
Jacquelin S, Licata F, Dorgham K, et al. CX3CR1 reduces Ly6Chigh-monocyte motility within and release from the bone marrow after chemotherapy in mice. Blood  2013; 122(5): 674-83.
[http://dx.doi.org/10.1182/blood-2013-01-480749] [PMID:  23775714] 
[122] 
Schall T. Fractalkine--a strange attractor in the chemokine landscape. Immunol Today  1997; 18(4): 147.
[http://dx.doi.org/10.1016/S0167-5699(97)84655-5] [PMID:  9136448] 
[123] 
Hesselgesser J, Horuk R. Chemokine and chemokine receptor expression in the central nervous system. J Neurovirol  1999; 5(1): 13-26.
[http://dx.doi.org/10.3109/13550289909029741] [PMID:  10190686] 
[124] 
Nishiyori A, Minami M, Ohtani Y, et al. Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett  1998; 429(2): 167-72.
[http://dx.doi.org/10.1016/S0014-5793(98)00583-3] [PMID:  9650583] 
[125] 
Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia  2002; 37(4): 314-27.
[http://dx.doi.org/10.1002/glia.10037] [PMID:  11870871] 
[126] 
Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA  1998; 95(18): 10896-901.
[http://dx.doi.org/10.1073/pnas.95.18.10896] [PMID:  9724801] 
[127] 
Milligan ED, Zapata V, Chacur M, et al. Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur J Neurosci  2004; 20(9): 2294-302.
[http://dx.doi.org/10.1111/j.1460-9568.2004.03709.x] [PMID:  15525271] 
[128] 
Wolf Y, Yona S, Kim KW, Jung S. Microglia, seen from the CX3CR1 angle. Front Cell Neurosci  2013; 7: 26.
[http://dx.doi.org/10.3389/fncel.2013.00026] [PMID:  23507975] 
[129] 
Lo HM, Lai TH, Li CH, Wu WB. TNF-α induces CXCL1 chemokine expression and release in human vascular endothelial cells in vitro via two distinct signaling pathways. Acta Pharmacol Sin  2014; 35(3): 339-50.
[http://dx.doi.org/10.1038/aps.2013.182] [PMID:  24487964] 
[130] 
Rittner HL, Mousa SA, Labuz D, et al. Selective local PMN recruitment by CXCL1 or CXCL2/3 injection does not cause inflammatory pain. J Leukoc Biol  2006; 79(5): 1022-32.
[http://dx.doi.org/10.1189/jlb.0805452] [PMID:  16522746] 
[131] 
Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell  2012; 150(1): 165-78.
[http://dx.doi.org/10.1016/j.cell.2012.04.042] [PMID:  22770218] 
[132] 
Zou A, Lambert D, Yeh H, et al. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins. BMC Cancer  2014; 14: 781.
[http://dx.doi.org/10.1186/1471-2407-14-781] [PMID:  25344051] 
[133] 
Dong F, Du YR, Xie W, Strong JA, He XJ, Zhang JM. Increased function of the TRPV1 channel in small sensory neurons after local inflammation or in vitro exposure to the pro-inflammatory cytokine GRO/KC. Neurosci Bull  2012; 28(2): 155-64.
[http://dx.doi.org/10.1007/s12264-012-1208-8] [PMID:  22466126] 
[134] 
Vallès A, Grijpink-Ongering L, de Bree FM, Tuinstra T, Ronken E. Differential regulation of the CXCR2 chemokine network in rat brain trauma: implications for neuroimmune interactions and neuronal survival. Neurobiol Dis  2006; 22(2): 312-22.
[http://dx.doi.org/10.1016/j.nbd.2005.11.015] [PMID:  16472549] 
[135] 
Ragozzino D. CXC chemokine receptors in the central nervous system: Role in cerebellar neuromodulation and development. J Neurovirol  2002; 8(6): 559-72.
[http://dx.doi.org/10.1080/13550280290100932] [PMID:  12476350] 
[136] 
Yang RH, Strong JA, Zhang JM. NF-kappaB mediated enhancement of potassium currents by the chemokine CXCL1/growth related oncogene in small diameter rat sensory neurons. Mol Pain  2009; 5: 26.
[http://dx.doi.org/10.1186/1744-8069-5-26] [PMID:  19476648] 
[137] 
Zhang ZJ, Cao DL, Zhang X, Ji RR, Gao YJ. Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons. Pain  2013; 154(10): 2185-97.
[http://dx.doi.org/10.1016/j.pain.2013.07.002] [PMID:  23831863] 
[138] 
Manjavachi MN, Costa R, Quintão NL, Calixto JB. The role of keratinocyte-derived chemokine (KC) on hyperalgesia caused by peripheral nerve injury in mice. Neuropharmacology  2014; 79: 17-27.
[http://dx.doi.org/10.1016/j.neuropharm.2013.10.026] [PMID:  24184386] 
[139] 
Chen G, Park CK, Xie RG, Berta T, Nedergaard M, Ji RR. Connexin-43 induces chemokine release from spinal cord astrocytes to maintain late-phase neuropathic pain in mice. Brain  2014; 137(Pt 8): 2193-209.
[http://dx.doi.org/10.1093/brain/awu140] [PMID:  24919967] 
[140] 
Orchard TS, Gaudier-Diaz MM, Phuwamongkolwiwat-Chu P, et al. Low sucrose, omega-3 enriched diet has region-specific effects on neuroinflammation and synaptic function markers in a mouse model of doxorubicin-based chemotherapy. Nutrients  2018; 10(12)E2004
[http://dx.doi.org/10.3390/nu10122004] [PMID:  30567351] 
[141] 
Hsu YL, Hung JY, Tsai EM, et al. Benzyl butyl phthalate increases the chemoresistance to doxorubicin/cyclophosphamide by increasing breast cancer-associated dendritic cell-derived CXCL1/GROα and S100A8/A9. Oncol Rep  2015; 34(6): 2889-900.
[http://dx.doi.org/10.3892/or.2015.4307] [PMID:  26397389] 
[142] 
Chen L, Pan XW, Huang H, et al. Epithelial-mesenchymal transition induced by GRO-α-CXCR2 promotes bladder cancer recurrence after intravesical chemotherapy. Oncotarget  2017; 8(28): 45274-85.
[http://dx.doi.org/10.18632/oncotarget.16786] [PMID:  28423359] 
[143] 
Wong J, Tran LT, Magun EA, Magun BE, Wood LJ. Production of IL-1β by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine. Cancer Biol Ther  2014; 15(10): 1395-403.
[http://dx.doi.org/10.4161/cbt.29922] [PMID:  25046000] 
[144] 
Zhou L, Hu Y, Li C, et al. Levo-corydalmine alleviates vincristine-induced neuropathic pain in mice by inhibiting an NF-kappa B-dependent CXCL1/CXCR2 signaling pathway. Neuropharmacology  2018; 135: 34-47.
[http://dx.doi.org/10.1016/j.neuropharm.2018.03.004] [PMID:  29518397] 
[145] 
Luo X, Wang X, Xia Z, Chung SK, Cheung CW. CXCL12/CXCR4 axis: an emerging neuromodulator in pathological pain. Rev Neurosci  2016; 27(1): 83-92.
[http://dx.doi.org/10.1515/revneuro-2015-0016] [PMID:  26353174] 
[146] 
Li M, Ransohoff RM. Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol  2008; 84(2): 116-31.
[http://dx.doi.org/10.1016/j.pneurobio.2007.11.003] [PMID:  18177992] 
[147] 
Guyon A. CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Front Cell Neurosci  2014; 8: 65.
[http://dx.doi.org/10.3389/fncel.2014.00065] [PMID:  24639628] 
[148] 
White FA, Wilson NM. Chemokines as pain mediators and modulators. Curr Opin Anaesthesiol  2008; 21(5): 580-5.
[http://dx.doi.org/10.1097/ACO.0b013e32830eb69d] [PMID:  18784482] 
[149] 
Memi F, Abe P, Cariboni A, MacKay F, Parnavelas JG, Stumm R. CXC chemokine receptor 7 (CXCR7) affects the migration of GnRH neurons by regulating CXCL12 availability. J Neurosci  2013; 33(44): 17527-37.
[http://dx.doi.org/10.1523/JNEUROSCI.0857-13.2013] [PMID:  24174685] 
[150] 
Dubový P, Klusáková I, Svízenská I, Brázda V. Spatio-temporal changes of SDF1 and its CXCR4 receptor in the dorsal root ganglia following unilateral sciatic nerve injury as a model of neuropathic pain. Histochem Cell Biol  2010; 133(3): 323-37.
[http://dx.doi.org/10.1007/s00418-010-0675-0] [PMID:  20127490] 
[151] 
Bai L, Wang X, Li Z, et al. Upregulation of chemokine cxcl12 in the dorsal root ganglia and spinal cord contributes to the development and maintenance of neuropathic pain following spared nerve injury in rats. Neurosci Bull  2016; 32(1): 27-40.
[http://dx.doi.org/10.1007/s12264-015-0007-4] [PMID:  26781879] 
[152] 
Reaux-Le Goazigo A, Rivat C, Kitabgi P, Pohl M, Melik Parsadaniantz S. Cellular and subcellular localization of CXCL12 and CXCR4 in rat nociceptive structures: physiological relevance. Eur J Neurosci  2012; 36(5): 2619-31.
[http://dx.doi.org/10.1111/j.1460-9568.2012.08179.x] [PMID:  22694179] 
[153] 
Xu T, Zhang XL, Ou-Yang HD, et al. Epigenetic upregulation of CXCL12 expression mediates antitubulin chemotherapeutics-induced neuropathic pain. Pain  2017; 158(4): 637-48.
[http://dx.doi.org/10.1097/j.pain.0000000000000805] [PMID:  28072604] 
[154] 
Li YY, Li H, Liu ZL, et al. Activation of STAT3-mediated CXCL12 up-regulation in the dorsal root ganglion contributes to oxaliplatin-induced chronic pain. Mol Pain 2017.131744806917747425
[http://dx.doi.org/10.1177/1744806917747425] [PMID:  29166835] 
[155] 
Matsushita K, Tozaki-Saitoh H, Kojima C, et al. Chemokine (C-C motif) receptor 5 is an important pathological regulator in the development and maintenance of neuropathic pain. Anesthesiology  2014; 120(6): 1491-503.
[http://dx.doi.org/10.1097/ALN.0000000000000190] [PMID:  24589480] 
[156] 
Gamo K, Kiryu-Seo S, Konishi H, et al. G-protein-coupled receptor screen reveals a role for chemokine receptor CCR5 in suppressing microglial neurotoxicity. J Neurosci  2008; 28(46): 11980-8.
[http://dx.doi.org/10.1523/JNEUROSCI.2920-08.2008] [PMID:  19005063] 
[157] 
Jo YH, Schlichter R. Synaptic corelease of ATP and GABA in cultured spinal neurons. Nat Neurosci  1999; 2(3): 241-5.
[http://dx.doi.org/10.1038/6344] [PMID:  10195216] 
[158] 
Fam SR, Gallagher CJ, Salter MW. P2Y(1) purinoceptor-mediated Ca(2+) signaling and Ca(2+) wave propagation in dorsal spinal cord astrocytes. J Neurosci  2000; 20(8): 2800-8.
[http://dx.doi.org/10.1523/JNEUROSCI.20-08-02800.2000] [PMID:  10751431] 
[159] 
Ochi-ishi R, Nagata K, Inoue T, Tozaki-Saitoh H, Tsuda M, Inoue K. Involvement of the chemokine CCL3 and the purinoceptor P2X7 in the spinal cord in paclitaxel-induced mechanical allodynia. Mol Pain  2014; 10: 53.
[http://dx.doi.org/10.1186/1744-8069-10-53] [PMID:  25127716] 
[160] 
Cataldo G, Erb SJ, Lunzer MM, et al. The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward. Neuropharmacology 2019.  107598.
[http://dx.doi.org/10.1016/j.neuropharm.2019.04.004] [PMID: 30970233] 
[161] 
Carr FB, Géranton SM, Hunt SP. Descending controls modulate inflammatory joint pain and regulate CXC chemokine and iNOS expression in the dorsal horn. Mol Pain  2014; 10: 39.
[http://dx.doi.org/10.1186/1744-8069-10-39] [PMID:  24947159] 
[162] 
Liu W, Ye J, Yan H. Investigation of key genes and pathways in inhibition of oxycodone on vincristine-induced microglia activation by using bioinformatics analysis. Dis Markers 2019.20193521746
[http://dx.doi.org/10.1155/2019/3521746] [PMID:  30881521] 
Rights & Permissions Print Cite
Article Metrics
31
2
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1389450120666190906153652	Print ISSN 1389-4501
Publisher Name Bentham Science Publisher	Online ISSN 1873-5592
当代药物靶点

趋化因子在化疗诱导的周围神经病变中的治疗潜力

摘要

图形摘要

当代药物靶点

趋化因子在化疗诱导的周围神经病变中的治疗潜力

摘要 Play Pause

图形摘要

Related Journals

Related Books

Related Articles

摘要
